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Multi-color lineage tracing reveals clonal dynamics of squamous 
carcinoma evolution from initiation to metastasis
Melissa Q. Reeves1,*, Eve Kandyba1, Sophie Harris1, Reyno Del Rosario1, and Allan 
Balmain1,*
1.Helen Diller Family Comprehensive Cancer Center, UCSF
SUMMARY
Tumor cells are subjected to evolutionary selection pressures during progression from initiation to 
metastasis. We analyzed the clonal evolution of squamous skin carcinomas induced by 
DMBA/TPA treatment using the K5CreER-Confetti mouse and stage-specific lineage tracing. We 
show that benign tumors are polyclonal, but only one population contains the Hras driver 
mutation. Benign papillomas are therefore monoclonal in origin, but recruit neighboring epithelial 
cells during growth. Papillomas that never progress to malignancy retain several distinct clones, 
whereas progression to carcinoma is associated with a clonal sweep. Newly generated clones 
within carcinomas demonstrate intratumoral invasion and clonal intermixing, often giving rise to 
metastases containing two or more distinct clones derived from the matched primary tumor. These 
data demonstrate that late stage tumor progression and dissemination are governed by evolutionary 
selection pressures that operate at a multicellular level, and thus differ from the clonal events that 
drive initiation and the benign-malignant transition.
INTRODUCTION
Most tumors are commonly thought to arise from the clonal expansion of a single, initiated 
cell1,2, followed by generation of distinct subclones that may cooperate to drive tumor 
growth or progression3,4. Inflammation of the tissue microenvironment leading to “field 
cancerization” (for review see Dotto5) and the discovery of oncogenic point mutations in 
groups of cells in histologically normal tissue6,7 have raised the possibility that multiple 
cells within a field can participate in the earliest stages of cancer development8–10. Studies 
using the dimethylbenzanthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA) skin 
carcinogenesis model have also identified stem-cell-like cells driving the distinct clonal 
growth patterns of benign and malignant tumors11,12. Although metastases were once 
thought to be clonal outgrowths of single disseminated tumor cells, both cell biological 13–16 
and genetic approaches17,18 have provided evidence for polyclonal contributions. Here we 
have exploited both multi-color cellular lineage tracing19 and next generation sequencing 
analysis of a mouse model which recapitulates the mutation burden and heterogeneity seen 
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in human tumors20–23 to interrogate clonal dynamics at multiple stages of tumor 
advancement, from initiation to metastasis.
RESULTS
The Confetti mouse contains a four-color cassette, which upon Cre-activation labels each 
cell with one of four fluorophores: GFP, YFP, RFP, or CFP19. Topical tamoxifen treatment 
of K5CreER-Confetti mouse backskin gave rise to durable (up to 18 months) labeling of 
skin cells with all four colors (Fig. 1A, B) with a slight bias in frequency19 for RFP (Fig. 
1C). Mice were treated with the carcinogen DMBA 10 days after their final dose of 
tamoxifen, to allow tamoxifen clearance24, and subsequent twice-weekly TPA treatment 25 
(Fig. 1D) generated benign papillomas beginning around 6-8 weeks.
Multiple cell populations contribute to benign papillomas
The majority of papillomas (75%) harvested at 20 weeks post-initiation showed mainly a 
single color (the “bulk color”) but had several, smaller populations of distinct colors also 
visible. These originated from the base of the tumor and formed “streaks” up the side of the 
papilloma (Fig. 2A), and were similar to patterns in papillomas observed in carcinogen-
treated chimaeric mice9. However early stage papillomas harvested at 12 weeks after DMBA 
treatment were single-colored (Fig. 2B, C), suggesting that the streak patterns developed 
over time and did not make a substantive contribution to the earliest papilloma growth. 
Analysis of papillomas harvested between 27 and 49 weeks after DMBA treatment showed 
patterns identical to those observed at 20 weeks. The increase in “streaked” papillomas 
between 12 weeks and both later timepoints was statistically significant (p=0.006 and 
p=0.00001 between 12 vs. 20 weeks and 12 weeks vs. terminal papillomas respectively) 
(Fig. 2C). Streaks comprised on average 6% (ranging from 1% to 17%) of colored cells in 
the tumor in both the 20-week and terminal cohorts, (Fig. 2D). Cross-sectioning of 
“streaked” tumors confirmed the whole-mount pattern (Fig. 2E, Supplementary Fig. 1A, B), 
and H&E staining of serial sections revealed no histological differences between cells that 
belonged to a streak and adjacent cells that did not (Fig. 2E-H).
We monitored tumors in two cohorts of control mice (either no tamoxifen, 217 tumors, 10 
mice; or no K5CreER cassette, 177 tumors, 7 mice) to determine whether stochastic 
recombination of the Confetti cassette could affect our observations. In both cohorts, we 
observed an extremely low level of Confetti leakiness. In a small number of papillomas—4 
papillomas from the “no tamoxifen” cohort (2.3%) and 10 papillomas from the “no 
K5CreER” cohort (4.6%)—one or two individual spots of color were observed. These were 
significantly smaller in size than the “streaks” described above (<15 cells) and lacked any 
trends in localization. Further, no leakiness was observed in carcinomas or metastases from 
either cohort (0/11 and 0/9 carcinomas and 0/8 and 0/9 metastases in “no tamoxifen” and 
“no K5CreER” cohorts respectively).
Minor cell populations are recruited cells, and papillomas are monoclonal in origin
To address the question of whether the “streaks” that develop during papilloma growth were 
genetically initiated cells, four multi-colored tumors were separated by fluorescence-
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activated cell sorting (FACS) (Fig. 3A, Supplementary Fig. 1C), followed by Sanger 
sequencing of Hras in “bulk” and “streak” cells from each papilloma22,26. We found a the 
expected Hras Q61L mutation in the bulk population of all four tumors, however, all the 
streak populations were wild-type for Hras by Sanger sequencing (Fig. 3B).
By sequencing whole exomes (Fig. 3B-H), we found that the streaks carried fewer total 
mutations (4.8 vs 13.3 mutations per megabase in the bulk population) (Fig. 3C). The bulk 
populations however carried a distinct DMBA-specific A>T mutation signature associated 
with mis-repair of adducts formed with adenosine residues in DNA27 and consistent with 
previous sequencing of tumors from this model22,28. Streak populations carried almost no 
A>T mutations and instead had a mutation signature primarily comprised of G>T mutations 
(Fig. 3D), possibly due to oxidative stress induced by the tumor promoter TPA22. In support 
of this, G>T mutations in these populations showed no strand bias, consistent with being 
reactive oxygen species (ROS)-induced and in contrast to the carcinogen-induced A>T 
mutations (Fig. 3F).
Further, while the bulk population carried gains of chromosome 7, effectively duplicating the 
mutant copy of the Hras gene located on this chromosome22,29, copy number profiles of the 
streak populations were completely silent (Fig. 3E). The mutation and copy number data 
together suggest that these streaks are derived from normal, neighboring K5+ keratinocytes 
(evidenced by the Confetti labeling) which were co-opted to grow and proliferate 
abnormally in the tumor.
Although the streak populations lacked the common Hras driver mutation and showed no 
sign of genomic instability, both bulk and streak populations alike carried potentially 
oncogenic mutations30–32 (Fig. 3G, Supplementary Table 1 & 2). In the bulk populations, in 
addition to Hras mutations, we found mutations in Trp53, Ep300, Fat1, and Ncor1, all of 
which we have previously reported to be recurrently mutated in DMBA-induced tumors22,28 
(Fig. 3G, Supplementary Table 1). In the streak populations, we detected two Notch 
mutations, Notch1 D545H and Notch2 P863H (Fig. 3G, Supplementary Table 2), both of 
which are in N-terminal epidermal growth factor (EGF)-like repeat domains responsible for 
Ca2+ binding. Interestingly, Notch mutations in this specific region are associated with 
squamous tumor development31 and have also been previously detected in DMBA-induced 
tumors22,28. Similar mutations in Notch have been found in histologically normal 
microdissected areas of human skin and have been proposed to confer a selective growth 
advantage7. We also detected a Pten M1R mutation, expected to result in a loss of translation 
of tumor suppressor Pten, and a stopgain mutation in Map3k1 (G1371X), which confers an 
early truncation in the kinase domain. Missense mutations and deletions of MAP3K1 are 
have been reported in a number of tumor types, including breast and prostate cancers33. 
These mutations together suggest that the streak populations, despite lacking an initiating 
Hras mutation, are subject to similar selection pressures as the bulk tumor.
We examined the variant allele fractions (VAF) of mutations in the bulk and streak 
populations to assess their respective clonalities. The average VAFs in the bulk populations 
were significantly higher than those in their respective streak counterparts (Fig. 3H, on 
average, VAF = 0.36 in bulk vs. 0.19 in streak populations, P < 2.2 × 10−16). This is 
Reeves et al. Page 3
Nat Cell Biol. Author manuscript; available in PMC 2019 March 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
consistent with the bulk population being a single population containing many clonal 
mutations (as well as some subclonal mutations acquired during continued tumor growth), 
while the sorted streak populations were each comprised of multiple populations (e.g., 
multiple streaks of the same color; see Fig. 2A). Finally, we asked whether the presence of 
mono-color patches in the interfollicular epidermis at the time of initiation could have 
masked polyclonal contributions to the “bulk” population of these tumors. Given the 
relatively small patch size (average 6–7 cells in cross-section) and the large number of 
papillomas collected (380 papillomas), such masking was statistically improbable, as a 
tumor lacking an obvious “bulk” color was never observed. We further looked at the mutant 
allele fraction of DMBA-associated T>A mutations in the bulk population of each tumor 
sequenced, which are expected to have a mutant allele fraction around 0.5 in a clonal 
population. The mean mutant allele fraction for T>A mutations was 0.43, with a unimodal 
distribution, in agreement with the “bulk” color population being comprised of a single 
initiated clone, and potentially a small number of cells belonging to matching-colored 
streaks.
Non-progressing papillomas harbor multiple equipotent clones, but a single clone drives 
progression to malignancy
In order to investigate the cellular dynamics of malignant progression, we next activated 
Confetti labeling in established early papillomas. DMBA/TPA-treated K5CreER-Confetti 
mice were given 2 doses of topical tamoxifen 8 weeks after DMBA treatment, when 
papillomas were typically 0.5–2mm in size (Fig. 4A). This resulted in widespread labeling 
of papillomas with all four Confetti colors (Fig. 4B), activating fluorescence in 
approximately 45% of tumor cells, as well as labeling of adjacent skin.
We monitored these mice over a period of 6–7 months after labeling, to compare clonal 
dynamics in papillomas that never underwent malignant progression to to those that 
progressed. In non-progressing papillomas, typically several large mono-color clones 
emerged (Fig. 4C-E) and persisted through the time of sacrifice 6 months later. In these non-
progressing papillomas, no significant clone intermixing occurred (Fig. 4F, G and 
Supplementary Fig. 2A-D), and no single dominant clone emerged within the tumor. 
Further, neighboring clones were histologically indistinguishable from one another 
(Supplementary Fig. 2A-D).
In contrast, a different pattern was seen in carcinomas that developed from papillomas in this 
same cohort of mice. Carcinomas, which were surgically resected when they reached 1cm in 
diameter, were all comprised of a single color clone (Fig. 4H, I). Approximately half (6/13) 
were entirely colored (3 RFP, 2 YFP, 1 CFP), while the others were entirely uncolored. 
Single-color patterns were confirmed by FACS for 11 of 13 tumors (remaining 2 carcinomas 
were not sorted) and by sectioning. To assess the significance of this, we compared this 
single-color pattern in carcinomas with the number of visible colored lobes in papillomas 
that were age-matched to a carcinoma or obtained at sacrifice. While carcinomas were 
comprised of only one color, papillomas contained on average 2.5 distinctly colored, 
externally visible lobes (p = 0.0003). This number is likely an underestimate, as only 
externally visible papilloma lobes were scored on whole-mount tumors. For example, 2 such 
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distinct lobes are seen in the right-hand whole-mount tumor in Fig. 4D, however cross-
sectioning of this tumor shown in Fig. 4E reveals at least 3 additional lobes (e.g., small CFP 
lobe in lower right, small RFP lobe in the middle, and GFP lobe at top previously 
indistinguishable from large YFP lobe).
It should be noted that in assessing carcinoma color, we focused on the tumor core. It is 
common for a carcinoma to grow partially beneath the skin, and so at the periphery it is not 
unusual to see hair follicles and interfollicular epidermis that differ in histology as well as 
color pattern from the tumor (Supplementary Fig. 2E), which we excluded from analysis. 
Further, although the streaks observed in papillomas could be detected in these carcinomas 
as well as carcinomas that developed from mice in the skin-labeling experiment described 
above, they were restricted to the periphery of the tumor (Fig. 4J). This suggests that 
whatever role these genetically more “normal” streaks might play in papilloma development, 
they are not essential to the tumor after progression to malignancy.
We conclude that while non-progressing premalignant tumors retain distinct clones, 
progression to malignancy is characterized by the sweep of a single clone, which dominates 
in malignant carcinomas.
Intratumoral invasion and clonal intermixing is a feature of carcinoma progression
In order to investigate clonal diversity and behavior during the benign-malignant transition 
itself, we next labeled papillomas at 24 weeks, closer to the time of progression (Fig. 5A, B). 
As in the 8-week labeling experiment, papillomas which did not progress to carcinomas over 
the following 6 months exhibited multiple colored regions. Carcinomas that emerged in this 
experiment, however, showed a range of labeling patterns, falling into three categories: 
multi-colored, speckled, and single-colored. These patterns appeared to correlate with the 
latency between tamoxifen labeling and carcinoma appearance and harvest (Fig. 5C), 
suggesting that we were able to observe snapshots of tumor dynamics at distinct points in 
time during progression.
In five carcinomas harvested between 2 and 6 weeks after labeling, we observed numerous 
distinctly-colored clones growing side by side (Fig. 5D-G, Supplementary Fig. 3). We 
observed that at the intersection of colored subclones, mixing of cell populations could be 
seen (Fig. 5F, Supplementary Fig. 4A), and that subclones could not be distinguished from 
each other by H&E (Fig. 5E, G). Distinct subclones, interestingly, displayed differential 
proliferative capacities, evidenced by levels of Ki67 staining (Supplementary Fig. 3). 
Whether the more proliferative subclone(s) would eventually come to dominate the 
carcinoma is unclear.
In contrast to this highly multi-color pattern in carcinomas that emerged shortly after 
labeling, carcinomas harvested 5 to 10 weeks after tamoxifen treatment typically exhibited a 
single dominant color clone, but also contained “speckled” patches in which cells of a 
distinct color were locally intermixed with the contiguous, dominant color clone (Fig. 6A-D, 
Supplementary Fig. 4B). Carcinomas could have multiple such localized speckle patches of 
distinct colors (Fig. 6C). These speckles displayed a pattern reminiscent of the border 
between two clones in the multi-color carcinoma (Fig. 5F), and were indistinguishable by 
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H&E (Fig. 6E). Neither the speckled cells nor the speckled regions showed particular co-
localization with microenvironmental structures, including lymphatic vessels (stained for 
with LYVE-1) or blood vessels (CD31) (Fig. 6F, G; Supplementary Fig. 5A). Squamous 
tumor speckles were positive for K14 (Supplementary Fig. 5B), consistent with this pattern 
being the result of intermixing of two tumor clones, rather than aberrant Confetti activation 
in a stromal or other cell type.
To address the possibility that the speckled subclones were the remnants of clones being 
outcompeted by the dominant clone, we quantified localized Ki67 levels in both populations. 
These data revealed that the speckled subclones were nearly always growing at the same rate 
or faster than the dominant clone with which they were locally intermixed (Fig. 6H). These 
observations, along with proliferation data from the multi-color tumors, rather indicate that 
carcinoma growth is driven by several, intermixed subclones, and further that these 
subclones emerge after the clonal sweep associated with progression to malignancy (Fig. 6I, 
J). This pattern is distinct from the equipotent clones observed in papillomas (Fig. 6I, J), 
which tended to remain localized to specific lobes with clear boundaries (Fig. 4E-G) rather 
than displaying the broad intermixing seen in carcinomas.
Metastasis can be polyclonal
Metastases in the DMBA/TPA tumor model develop after surgical resection of the primary 
tumor, mimicking the course of human clinical practice and making it a uniquely suitable 
model for interrogating the patterns of clonal evolution that take place during tumor 
dissemination to distant sites. For mice in all Confetti labeling cohorts, primary carcinomas 
were surgically removed when they reached 1cm in diameter, enabling prolonged survival of 
the animals and subsequent harvesting of any metastases that developed. On average, mice 
received their first surgery 32 weeks after DMBA treatment (range: 26-43 weeks), and 
survived an additional 6 weeks (range: 2-16 weeks). We collected a total of 40 metastases 
from 14 mice labeled at either of the two earlier timepoints (e.g., labeling of pre-initiation 
skin or 8-week papillomas), and these were uniformly single-colored (Fig. 7A, B), 
consistent with the clonal patterns in carcinomas in these mice. Further, in the majority of 
mice (9/12, 75%) in which multiple metastases were collected, metastases to distinct 
locations were the same color as one another, with as many as 8 matching-colored 
metastases found in one mouse (Fig. 7A, B). This is in agreement with previously published 
phylogenetic trees from this model demonstrating that most commonly, all metastases arise 
from the same primary tumor22. This prior work23 suggested that metastatic dissemination 
occurs before surgical resection of the primary tumour, and in some cases at relatively early 
stages of tumor development, as shown by the existence of many “private” mutations that 
are unshared between primary carcinomas and their matched metastases. Our data showing 
that metastases from animals with early Confetti activation are invariably comprised of one 
single color could either mean that metastasis is a clonal event, or that polyclonal 
dissemination took place after an early clonal sweep, followed by generation of distinct 
genetic subclones of the same color.
To address these possible scenarios, we investigated the clonality of the metastases in mice 
in which Confetti labeling occurred at 24 weeks—the only cohort bearing multi-color 
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primary carcinomas. We collected 12 metastases from 5 mice, and observed metastases 
comprised of multiple distinctly-colored cellular populations in 3 of the 5 mice (Fig. 7C). 
While this cohort was small, the finding of multi-colored metastases in 3 mice (60%) was 
significant compared to 0/14 mice (0%) in the earlier cohorts (p = 0.010, Fisher’s exact test). 
In one case, we observed 3 multi-color metastases in the same animal, with two lymph node 
metastastases and a lung metastasis all comprised of a mix of RFP and YFP cells (Fig. 7C).
For two additional cases of multi-color metastases, we used exome sequencing to ask 
whether the distinct cell populations in each metastasis were from the same primary tumor. 
The first case we sequenced was a lymph node metastasis in which K14+ cells (i.e., tumor 
cells) were 75% uncolored and 25% GFP+, and intermixed in a speckling pattern (Fig. 7D). 
The lymph node metastasis shared 350 mutations with one of three primary carcinomas in 
the mouse (Carcinoma A) (Fig. 7E, F). We could not initially be certain whether these 350 
mutations were present in both the uncolored and GFP+ cells in the metastasis, so we asked 
whether mutations in the other carcinomas (Carcinoma B and Carcinoma C, Fig. 7E) were 
present at low levels in the metastasis, particularly in loci well-covered by sequencing reads 
(>50×), and found they were not. We also examined mutations in the metastasis that were 
not shared with Carcinoma A for contributions from an unidentified primary tumor, which 
would have contributed its own fingerprint of DMBA-induced T>A signature mutations22—
however, we found only 4 T>A mutations in the metastasis that were not present in 
Carcinoma A. We conclude that no evidence exists in the sequencing data that would 
support the possibility that the uncolored cells and GFP+ cells in this metastasis originated 
from different primary tumors but rather, both cell populations arose from Carcinoma A.
Interestingly, Carcinoma A was a predominantly uncolored tumor with a significant GFP+ 
speckle region, visible in the middle and right of the tumor cross section (Fig. 7F). Both the 
uncolored cells and GFP+ cells in this region were highly proliferative (Fig. 7G, H, 62% and 
56% Ki67+ respectively). This carcinoma also contained YFP+ and RFP+ speckle regions, 
visible at the left side of the cross section (Fig. 7F). However despite the presence of these 
YFP+ and RFP+ cells in the primary tumor, apparently only the GFP+ and uncolored 
populations contributed to metastasis.
We performed exome sequencing on a second case of multi-color metastasis, a lymph node 
metastasis from another mouse which contained both RFP+ and uncolored K14+ tumor cells 
(Supplementary Fig. 6A). In this case, we sorted the RFP+ and uncolored populations by 
FACS (Supplementary Fig. 6B), sequenced, and again confirmed that they originated from 
the same primary tumor on the basis of shared mutations and shared copy number alterations 
(Supplementary Fig. 6C).
We conclude that metastases, in contrast to the earlier stages of tumor progression, do not 
arise from a single cell within the primary tumor that has acquired metastatic properties, but 
rather that multiple cells within progressed lesions have the capacity to disseminate and seed 
at distant sites. These data therefore agree with a polyclonal model of metastatic 
dissemination. Notably, the distinct clones seen in metastases showed the pattern of intimate 
intermixing (Fig. 7D) that was a feature of progression to carcinoma.
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DISCUSSION
We have exploited multi-color lineage tracing using the Confetti mouse to investigate the 
clonal dynamics that govern each stage of tumor progression from initiation to metastasis. 
Others had previously used mouse models to demonstrate that papillomas were possibly 
polyclonal in origin9, or that DMBA-initiated papillomas can contain cells that do not harbor 
the known initiating HrasQ61L mutation10. Our data demonstrate that these cells were not 
co-initiators of the papilloma, as they lacked the genetic changes, including the initiating 
Hras mutation, trisomy of chromosome 7 and DMBA mutation signature, that are 
characteristic of papillomas. This implies that the presence of multiple cellular populations 
in the tumor is not in itself evidence of true polyclonal initiation, although it has historically 
been interpreted as such in studies of both mouse models and human tumors34,35. The 
streaks we observed were reminiscent of a similar radial streaking pattern displayed by 
lineage-tracing of Krt15+ hair follicle bulge stem cells during wound healing36, calling to 
mind the analogy of a tumor to a wound that never heals37. However, their presence appears 
to not be necessary for progression to carcinoma, as they become increasingly marginalized 
during malignant conversion. Interestingly, Krt15-positive stem cells also make only a 
transient contribution to normal healing wounds36,38.
Labeling of established papillomas at 8 or 24 weeks after initiation allowed us to detect 
distinct patterns of clonal evolution during progression to malignancy. Papillomas that had 
not progressed after 6 months consisted of 2-4 distinct colored clones (Fig. 6I) which could 
have arisen from rare papilloma stem cells11,12. However, progression to carcinoma occurred 
after a clonal sweep resulting in the emergence of one dominant clone. Labeling papillomas 
at 24 weeks showed that most carcinomas that emerged within the next 10 weeks contained 
two or more intermixed, proliferating cellular populations (Fig. 6J), that may represent 
functionally distinct cells that cooperate, through paracrine or juxtacrine interactions3,4. 
Similar processes may contribute to tumor dissemination, as multiple carcinoma clones 
frequently participated in metastasis. Such clonal cooperativity has been observed in small-
cell lung cancer cell lines in vitro and in vivo3, and in a model of MMTV (mouse mammary 
tumor virus)-driven breast cancer4, and even during bacterial evolution over thousands of 
generations in culture39. Given the importance of cellular and genetic heterogeneity in 
human cancer prognosis40, further studies of this symbiosis may foster development of new 
approaches to inhibit these interactions for cancer therapy.
METHODS
Mice and carcinogenesis.
To induce tumors, male and female K5CreER-Confetti FVB/N mice were shaved and treated 
with 25mg DMBA dissolved in 200μL acetone either 10 days after final dose of tamoxifen 
(skin activation experiment) or at 8 weeks of age (tumor activation experiments). Mice 
subsequently received TPA (200μL of a 10−4 M solution in acetone) twice a week for 20 
weeks, following established chemical carcinogenesis protocol25. Carcinomas were 
surgically resected when they reached a size of >1 cm in longest diameter, and mice given 
0.24mL meloxicam (Boehringer Ingelheim, 5mg/mL solution) for recovery. Mice were 
sacrificed when disease progressed, per animal care requirements. At sacrifice, papillomas 
Reeves et al. Page 8
Nat Cell Biol. Author manuscript; available in PMC 2019 March 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and carcinomas were removed from skin, and all internal tumors were resected. All animal 
experiments were approved by the University of California San Francisco Laboratory 
Animal Resource Center (protocol approval #AN159869). This work complies with all 
relevant ethical regulations regarding animal research.
Confetti labeling.
Tamoxifen (Sigma) was dissolved overnight in sunflower seed oil at a concentration of 
10mg/mL. Mice were treated with 400μL (4mg) per dose, applied to the back skin topically, 
and were shaved the day prior to first treatment. For skin activation experiment, mice were 
given 4 doses every other day for a total of 16mg. For tumor activation experiments, mice 
were given 2 doses for a total of 8mg, spaced 2 days apart, at either 8 or 24 weeks.
Tissue harvesting.
Skin, tumor, and metastatic tissues harvested for sectioning were kept at 4°C in 10% 
formalin overnight, in a gradient of 15% / 20% / 30% sucrose on the second day, in 30% 
sucrose overnight the second night, and then embedded in OCT (Tissue-Tek, Sakura) and 
stored at −80°C until sectioning.
Digestion for FACS.
For tumors that were FACS sorted, a piece of the tumor was first removed for embedding in 
OCT and imaging. For carcinomas, skin tissue along the edge of the carcinoma was also 
removed. Tumors were then finely chopped, washed with PBS, digested in 4mg/mL 
Collagenase A (Sigma-Aldrich) for 1 hour at 37°C, and then resuspended in 0.25% Trypsin-
EDTA (Gibco Life Technologies) and incubated on a shaker at 37°C for 1 hour. Trypsin was 
neutralized with an equal volume of FBS, and digested tumor filtered through a 40μm filter, 
pelleted, and resuspended in FACS buffer (2% FBS) for sorting.
Quantification of Confetti labeling.
To quantify Confetti activation in the skin, a strip of skin oriented along the spine was 
collected for 5 mice 10 days after the final dose of tamoxifen, e.g., the day that DMBA 
treatment would have begun. To quantify Confetti activation in tumors, papillomas were 
surgically removed 3 days after the final dose of tamoxifen. Tissues were harvested and 
embedded in OCT as described above, and 5μm sections were taken for quantification. For 
each sample, a minimum of 10 images were taken at 40× with a 6D Nikon microscope, and 
nuclei and colored cells of each color were manually counted in ImageJ.
Quantification of multi-color papillomas.
At sacrifice, back skin was removed intact from mouse and imaged whole on an MVX10 
fluorescent stereoscope, which could distinguish RFP, CFP, and YFP/GFP. YFP and GFP 
were not distinguishable from each other under this microscope. Tumors on each back skin 
were counted, and color(s) recorded. For statistical calculations (e.g., Figure 2C), mice 
which had fewer than 3 papillomas were excluded as they did not provide sufficient data 
(this led to the exclusion of 2 mice).
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Quantification of streak populations.
To calculate the percent of colored cells comprised by streak populations, number of sorted 
RFP, CFP, and YFP/GFP cells were used. Due to weakness of the CFP fluorophore, bulk-
CFP tumors (CFP confirmed by sectioning) were widely variable as to the number of CFP+ 
cells that could be collected; to reduce the large amount of noise introduced by this, we used 
only bulk-RFP, bulk-YFP, and bulk-GFP tumors for these calculations.
Nucleic acid extraction.
DNA was extracted from tumors using Qiagen DNeasy Blood & Tissue Kit, following 
manufacturer’s instructions. In cases where DNA was extracted after FACS sorting, protocol 
was modified as follows to improve yield: (1) After sorting, FACS collection tube was spun 
down at 3,000rpm for 10 minutes and cells resuspended in 200μL PBS before initial lysis 
step; (2) Wash step with buffer AW2 was done twice. DNA concentration and quality were 
determined by Nanodrop spectrophotometry.
Sanger sequencing of Hras locus.
Hras locus containing codon 61 was PCR amplified using primer pair 
AAGCCTGTTGTTTTGCAGGA (forward) and GGTGGCTCACCTGTACTGATG 
(reverse). PCR product was purified using Exonuclease I (USB) and Shrimp Alkaline 
Phosphatase (Affymetrix), and Sanger sequencing was performed using the forward primer 
listed above by MCLAB. Images were taken using FinchTV.
Exome sequencing.
DNA samples were submitted to Otogenetics Corporation (Atlanta, GA) for mouse exome 
capture and sequencing. Illumina libraries were made from qualified fragmented gDNA 
using SPRIworks HT Reagent Kit (Beckman Coulter) and the resulting libraries were 
subjected to exome enrichment using SureSelectXT Mouse All Exon (Agilent) following 
manufacturer’s instructions. Enriched libraries were tested for enrichment by qPCR and for 
size distribution and concentration by an Agilent Bioanalyzer 2100. The samples were then 
sequenced on an Illumina HiSeq2500 using Rapid v2 SBS chemistry which generated 
paired-end reads of 106 nucleotides.
Sequence alignment, processing and quality control.
Reads were mapped to the GRCm38/mm10 version of the Mus musculus genome using 
BWA (version 0.7.12)41 with default parameters. The Picard MarkDuplicates module was 
used to remove duplicates from the data (version 1.131; http://broadinstitute.github.io/
picard). The Genome Analysis Tool Kit (GATK-Lite) toolkit (version 2.3-9)42 module 
IndelRealigner and BaseRecalibrator were used to preprocess the alignments. During base 
quality recalibration, dbSNP variants were used as known sites, according to GATK Best 
Practices recommendations43. Finally, alignment and coverage metrics were collected using 
Picard. We sequenced an average of 42 million unique reads per sample. Targeted bases 
were sequenced to a mean depth of 50, and more than 75% of targeted bases were sequenced 
to 20× coverage or greater.
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Variant calling.
SNVs were called using somatic variant detection program MuTect (version 1.1.7)44. Each 
tumor was called against its matched normal tissue (tail), and calls were filtered against a 
database of known Mus musculus germline SNPs available at ftp.ncbi.nih.gov/snp/
organisms/mouse_10090/VCF/genotype, as well as against a panel of normal tails from this 
experiment. Results were further filtered to calls with a minimum read depth of 10 at the 
locus for both tumor and matched normal, and to calls where at least one alternate read had a 
mapping quality score of 60 or higher. Variants were annotated using Annovar (downloaded 
on 2/4/2016)45, and these annotations were used as the basis for assessing exonic variants as 
synonymous, nonsynonymous, stopgain, or stoploss. Mutations in cancer-associated genes 
were identified, where cancer-associated genes were considered to be those commonly 
mutated in head and neck squamous cell carcinoma31 or cutaneous skin squamous cell 
carcinoma32 in The Cancer Genoma Atlas data, or on a previously published list of cancer 
driver genes30.
Copy number calling was done with CNVkit46, and tumor copy number status was called 
against a panel of normal tails from the same sequencing batch.
Mutation context.
For mutation spectrum analysis, SNVs in all tumors were annotated with 1 of 96 possible 
trinucleotide context substitutions (6 types of substitutions × 4 possible flanking 5’-bases × 4 
possible flanking 3’-bases), using MuTect output, and counts of each mutation context were 
summed.
Phylogenies.
To build phylogenetic trees, absolute distance matrices were calculated based on the 
presence of mutations in the sample, based on filtered MuTect calls. Rooted trees were built 
with use of the Analyses of Phylogenetics and Evolution (APE) package and manhattan 
calculation method implemented in R version 2.15. Relationships between metastases and 
primary tumors were determined on the basis of shared mutations.
Quantification of colored lobes in papillomas labeled at 8 weeks.
Papillomas were imaged whole on an MVX10 fluorescent stereoscope. Images were taken to 
record observations, and these whole-tumor images were used to count the number of 
distinctly-colored lobes on each tumor. It was possible to identify RFP, CFP, YFP/GFP, and 
uncolored lobes, however YFP and GFP could not be distinguished from each other using 
this microscope. Selected tumors from this cohort were also embedded in OCT as described 
above, sectioned, and 5μm sections were imaged with a Nikon 6D scope to confirm lobe 
quantifications done with the whole-mount tumor. Results from imaging these sections 
correlated well with whole-mount observations. For statistical analysis, in comparing 
number of colored lobes in papillomas and carcinomas, we excluded fully-uncolored 
papillomas and carcinomas because it is impossible to distinguish a monoclonal tumor from 
a poorly-labeled polyclonal tumor with multiple uncolored subclones; thus, we included 
only tumors where at least one Confetti color was visible in the analysis.
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Classification of labeling pattern in tumors labeled at 24 weeks.
For carcinomas harvested in 24 week labeling experiment, all carcinomas were embedded in 
OCT as described above, sectioned, and imaged with a Nikon 6D microscope in order to 
classify their labeling pattern. At least two distinct pieces of each carcinoma were used, and 
at least 3 serial sections taken 100μm or more apart. Tumors classified as multi-color 
contained large, contiguous patches of at least 2 of the 4 Confetti colors. Tumors classified 
as speckled showed one or more “speckle” populations of cells that were a distinct color 
from the surrounding tumor cells, and which formed localized patches of non-contiguous 
cells (in contrast to contiguous patches observed in “multi-color” tumors), and which could 
be identified in at least 3 serial sections from the tumor. Tumors classified as single-color 
contained only one color population of cells in the tumor, excluding hair follicles and 
interfollicular epidermis that was sometimes present at the edge of the tumor.
Immunofluorescent staining.
Slides with 5μm tumor sections were brought to room temperature, post-fixed in 4% 
paraformaldehyde for 8 minutes, and washed in PBS for 5 minutes. For Ki67 staining, slides 
were blocked in 5% goat serum/0.3% Triton-X100 for 1 hour. Ki67 antibody (Cell Signaling 
#9129) was used at a concentration of 1:300 in 2% goat serum/0.3% Triton-X100 and left on 
slides overnight. Slides were washed 3× in PBS, and incubated with goat anti-rabbit Alexa 
Fluor 647 (Thermofisher #A21246) secondary antibody at a concentration of 1:200 for 90 
minutes, and then washed 2× with PBD (PBS with 0.1% Tween-20) followed by PBS. For 
K14, LYVE-1, and CD31 staining, slides were blocked in 10% donkey serum/0.1% Triton-
X100 for 15 minutes. K14 antibody (Biolegend #905301) was used at a concentration of 
1:2000, and allowed to incubate on slides for 2 hours. For lymphatic vessel staining, 
LYVE-1 antibody (Abcam #ab14917) was used at the concentration of 1:100, and allowed to 
incubate on slides for 2 hours. For blood vessel staining, CD31 antibody (Abcam #ab28364) 
was used at a concentration of 1:300, and allowed to incubate on slides for 2 hours. For K14, 
LYVE-1 and CD31 staining, secondary antibody of either donkey anti-rabbit Alexa Fluor 
594 (Thermofisher, A21207) or Alexa Fluor 488 (Thermofisher #A21206) was selected to 
avoid interference with Confetti colors in relevant samples, and slides were incubated with 
secondary antibody at a concentration of 1:500 for 1 hour and washed 3× with PBS.
Quantification of Ki67.
Tumor sections stained for Ki67 were imaged with a Nikon 6D microscope. Quantification 
was based on manual counts using ImageJ of at least 3 images taken at 40× magnification, 
where individual cells could be identified and classified based on both presence or absence 
of Ki67 and Confetti labeling color.
Statistics and reproducibility.
Statistics and P-values throughout the manuscript were calculated with Student’s two-tailed 
t-test, using R (version 3.2.3). For Fig. 2c, 2d, 3h, 5c, 5m, and 6g, two-sample t-tests were 
performed to calculate difference between two distributions as shown. For Fig. 3f one-
sample t-test was performed for each sample to evaluate null hypothesis of mean equal to 
0.5 (i.e., even distribution of mutation between strands). Skin labeling experiment was 
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performed in 8 mice for 12-week observation, 4 mice for 20-week observation, and 9 mice 
for observation of terminal disease, with reproducible results between all mice in each 
cohort. 8-week labeling experiment was performed in 4 mice, divided into 2 cohorts, with 
reproducible results between all mice. 24-week labeling experiment was performed in 5 
mice, divided into 3 cohorts, with reproducible results between all mice.
Data availability
Exome sequence data that support the findings of this study have been deposited in the 
European Nucleotide Archive under accession number ERP107810. Source data for Fig. 1c, 
2c, 2d, 3c, 3d, 3f, 5c, 6h, and 7g have been provided as Supplementary Table 3. All other 
data supporting the findings of this study are available from the corresponding author on 
reasonable request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Tamoxifen-induced Confetti labeling of the skin.
(A and B) Back skin sections of K5CreER-Confetti mice (5 mice), treated with 4 doses of 
tamoxifen to activate Confetti recombination. Sections taken 10 days after final dose of 
tamoxifen, at 10× (A) and 40× (B) magnification.
(C) Proportion of labeled skin cells in back skin expressing each Confetti fluorophore, 10 
days after final dose of tamoxifen (n=3 mice, 44 panels). See Supplementary Table 3 for 
statistics source data.
(D) Schematic of tumorigenesis strategy. K5CreER-Confetti mice are treated with 4 doses of 
tamoxifen to activate Confetti labeling, and then treated with the carcinogen DMBA 10 days 
after final tamoxifen dose, followed by biweekly treatments with tumor promoter TPA. 
Dozens of benign papillomas emerge beginning at 6-8 weeks, a subset of which progress to 
carcinomas. Carcinomas are surgically resected when they reach 1cm in diameter, and mice 
go on to develop metastatic disease.
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Figure 2. Streaked appearance of papillomas arising from Confetti-labeled skin.
(A) Whole papillomas with multi-color streaking pattern, characteristic of 20-week 
papillomas (77 tumors), viewed from a fluorescent dissecting microscope. Left panel views 
the papilloma from the side, center and right panels view papillomas from the bottom.
(B) Whole papilloma lacking streaking pattern, characteristic of 12-week papillomas (222 
tumors), viewed from a fluorescent dissecting microscope from the side.
(C) Percentage of papillomas in each mouse that exhibited a multi-color pattern, organized 
by time point at which papillomas were harvested. Data based on 222 12-week tumors (n=8 
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mice), 77 20-week tumors (n=4 mice), and 81 terminally benign tumors (n=9 mice). Box 
plots show boxes extending from first to third quartile, with median marked by a cross bar. 
Asterisk (*) indicates P < 0.05, two-sided Student’s t-test.
(D) Streak cells as a percentage of colored cells in a multi-color papilloma. Data based on 
n=15 twenty-week and n=9 terminal FACS-sorted tumors. Cross-bar shows mean in each 
cohort.
(E) Cross-section of a multi-color, streaked papilloma, characteristic of 20-week and 
terminal papillomas (77 and 81 tumors respectively). The bulk of the papilloma is CFP+, 
and RFP+ and YFP+ streaks are visible. Nuclei are marked with DAPI.
(F) H&E of adjacent section of papilloma shown in panel (E).
(G) Close up of RFP+ and YFP+ streaks in CFP+ papilloma at 40× magnification. Nuclei 
are marked with DAPI.
(H) H&E of adjacent section of papilloma region shown in panel (G). Cell belonging to bulk 
CFP+ and to streak RFP+ and YFP+ populations are pathologically indistinguishable. See 
Supplementary Table 3 for statistics source data.
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Figure 3. Genetic analysis of bulk and streak papilloma populations.
(A) Whole-tumor fluorescent dissecting scope images of the 4 multi-color papillomas 
separated for sequencing of “bulk” and “streak” populations.
(B) Sanger sequencing of Hras in bulk (top) and streak (bottom) population in a multi-color 
tumor (n = 4 tumors). Arrow shows chr7:141192550; when mutated to T this results in an 
Hras Q61L mutation.
(C) Mutation rate per megabase, based on exome sequencing to 50×, of 4 bulk, 5 streak 
populations.
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(D) Trinucleotide context of mutations in 4 bulk, 5 streak populations. X-axis denotes 96 
possible trinucleotide contexts, grouped by base pair change. T>A mutations (yellow) are 
frequent in bulk population but near-absent in streak populations. C>A(G>T) mutations are 
observed in both populations.
(E) Copy number alterations. Chromosomes arranged along X-axis; samples arranged on Y-
axis in same order as panel (C). Gains of chromosome 7, on which Hras is located, observed 
in all 4 bulk populations; no copy number alterations are observed in streak populations.
(F) Frequency of each base on the coding strand being mutated for T>A(A>T) (yellow) and 
G>T(C>A) (blue) mutations (n = 9 samples). T>A(A>T) mutations showed a bias for “A” 
on the coding strand at the mutated site; G>T(C>A) mutations showed no bias. Bar graphs 
show mean±s.e.
(G) Comparison of cancer-associated mutations in bulk and streak samples (right, each 
column represents one sample) with frequency of mutation in these genes in a previously 
published cohort23 (right). Variant allele frequency (VAF) color-coded dark green for 
mutations present in >20% of reads, and light green for <20%. Note that although a 
mutation in Hras was detected in a single streak sample, it was present at a low allele 
fraction.
(H) VAFs of mutations in bulk and streak samples (n = 573, 181, 932, 322, 339, 107, 135, 
845, 56 mutations, left to right). Samples organized by tumor of origin; in each case VAFs in 
the bulk population are higher consistent with a population of clonal origin. Box plots 
extend first to third quartile; median marked by crossbar; P-values based on two-sided 
Student’s t-test. Supplementary Table 3 for source data.
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Figure 4. Tumor evolution following Confetti labeling at 8 weeks.
(A) Schematic of experimental design. DMBA/TPA-induced papillomas were allowed to 
grow for 8 weeks in K5CreER-Confetti mice. Confetti labeling was subsequently activated 8 
weeks after DMBA treatment with 2 doses of tamoxifen, and TPA treatment was continued.
(B) Cross-section of a papilloma labeled at 8 weeks post-DMBA, 3 days after final dose of 
tamoxifen, exhibiting Confetti labeling (3-day labeling verification based on 3 tumors).
(C, D) Whole papillomas labeled at 8 weeks post-DMBA (25 papillomas), viewed from with 
side with a fluorescent dissecting microscope. Images taken 8 weeks (D) and 27 weeks (C) 
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after tamoxifen. Green and red lobes are visible in (C) and right-hand tumor in (D), blue 
lobe and small red lobe are visible in left-hand tumor in (D).
(E) Cross-section of right-hand tumor in (D), a papilloma labeled at 8 weeks post-DMBA. 
Image taken 8 weeks after tamoxifen. Nuclei are marked with DAPI.
(F and G) High magnification images of tumor shown in (E), highlighting boundaries 
between colored lobes where limited intermixing is seen. Nuclei are marked with DAPI.
(H and I) Cross-sections of carcinomas from mice in which Confetti labeling was activated 8 
weeks post-DMBA, each exhibiting only a single color (13 carcinomas). Nuclei are marked 
with DAPI.
(J) Whole carcinoma from a mouse treated with tamoxifen at 8 weeks (13 carcinomas), 
viewed from the top (left) and side (right). Streaks, indicated by arrows, are visible but 
confined to the periphery.
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Figure 5. Carcinoma evolution following Confetti labeling at 24 weeks.
(A) Schematic of experimental design. DMBA/TPA-induced papillomas were allowed to 
grow for 24 weeks in K5CreER-Confetti mice. Confetti labeling was subsequently activated 
with 2 doses of tamoxifen.
(B) Cross-section of a papilloma labeled at 24 weeks post-DMBA, 3 days after final dose of 
tamoxifen, exhibiting Confetti labeling (3-day labeling verification based on 2 tumors).
(C) Relationship between labeling pattern observed in harvested carcinomas and the time 
elapsed between tamoxifen labeling and harvest. Carcinomas harvested close to time of 
labeling were frequently multi-color (n = 5), carcinomas harvested at an intermediate time 
point were frequently speckled (n = 7), and carcinomas harvested long after labeling were 
typically single colored (n = 9). Asterisk (*) indicates P < 0.05, two-sided Student’s t-test. 
See Supplementary Table 3 for statistics source data.
(D) Cross-section of a multi-color carcinoma exhibiting patches of all Confetti colors.
(E) H&E of adjacent section of carcinoma shown in panel (D).
(F) Magnified region of multi-color carcinoma shown in panel (D), showing intermixing of 
colored cells at a boundary between RFP, CFP, and GFP clones.
(G) H&E of adjacent section of carcinoma region shown in panel (F). Cells belonging to 
CFP+, RFP+ and GFP+ clones are indistinguishable by H&E.
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Figure 6. Speckle populations observed in carcinomas.
(A, B) Examples of colored carcinomas containing colored “speckles.” RFP-dominant 
carcinoma with YFP speckles (A) and CFP-dominant carcinoma with YFP speckles (B). 
Example “speckle” cells indicated with arrows.
(C) Carcinoma containing multiple patches of differently-colored speckles. 3 of 7 speckled 
carcinomas displayed multiple differently-colored speckle patches. Carcinoma shown is 
dominated by uncolored cells (nuclei marked with DAPI), and contains YFP and RFP 
speckles, each localizing to distinct regions (arrows).
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(D) High magnification image of a dominant-uncolored carcinoma containing YFP+ and 
GFP+ speckles.
(E) H&E of adjacent section of carcinoma region shown in panel (D). Cells belonging to 
uncolored, YFP+ and GFP+ clones are indistinguishable by H&E.
(F, G) Speckled carcinomas stained for LYVE-1 (F) and CD31 (G) (4 tumors stained, 5 
sections each). No trends in localization are observed between speckles and blood vessels 
(CD31) or lymphatic vessels (LYVE-1).
(H) Relative levels of Ki67+ staining between dominant and speckle populations in selected 
local regions, representing tumors from multiple mice (counts based n = 6, 3, 6, 3, 3 sections 
for tumors, left to right). Bar graphs show mean±s.e. See Supplementary Table 3 for 
statistics source data.
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Figure 7. Evidence for polyclonal seeding of metastasis.
(A and B) Metastases to the chest wall (A) and lung (B) from a mouse in which skin was 
labeled pre-initiation (experimental design described in Fig. 1D, 10 mice), viewed from a 
fluorescent dissecting microscope. All metastases are from the same mouse, and are 
uniformly red (RFP+). The same pattern was observed in mice in which papillomas were 
labeled at 8 weeks (4 mice).
(C) Lung metastasis from a mouse in which papillomas were labeled at 24 weeks 
(experimental design described in Fig. 5A, 5 mice), viewed from a fluorescent dissecting 
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microscope, containing both red (RFP+) and green (YFP+) cells. Lung is outlined with a 
dashed line.
(D) Cross-section of a lymph node metastasis from a second mouse in which papillomas 
were labeled at 24 weeks (experimental design described in Fig. 5A, 5 mice), exhibiting a 
dominant uncolored cell population and GFP+ speckles (left). K14 staining of the same 
panel (right) demonstrates both uncolored and GFP+ cells are K14+ tumor cells.
(E) Phylogenetic tree showing relationship between all tumors in mouse bearing lymph node 
in panel (D). Carcinoma A (shown in panel (F)) and the lymph node metastasis share 350 
mutations. Mutations and phylogenetic tree based on exome sequencing performed to a 
target depth of 50× for the four tumors shown (Carcinoma A, B, and C and the lymph node 
metastasis).
(F) Cross-section of sequence-matched Carcinoma A that gave rise to lymph node metastasis 
in panel (D). Carcinoma contains YFP, RFP, and GFP speckle patches indicated with arrows.
(G) Quantification of Ki67 staining of GFP+ and uncolored cells in the GFP speckle region 
in Carcinoma A, showing similar Ki67 levels in both populations. Staining and 
quantification was done in the region adjacent to right-most arrow in panel (F) (n = 6 
sections). Bar graphs show mean±s.e. See Supplementary Table 3 for statistics source data.
(H) Illustrative Ki67 staining of GFP speckle region, quantified in panel (G).
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